Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Strength in Bio Rad's (BIO) key product lines across major geographic regions buoys optimism.

Bio Rad (BIO) Grows Internationally on New Product Launches

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Is Bio-Rad Laboratories (BIO) Outperforming Other Medical Stocks This Year?

If you are looking for stocks that are well positioned to maintain their recent uptrend, Bio-Rad (BIO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in Bio-Rad (BIO) is Your Friend, Here's Why

Strength in the Life Science and Clinical Diagnostics segments drove Bio-Rad's (BIO) revenues in the third quarter.

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, 2021 View Raised

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q3 2021 Results - Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 61.30% and 11.33%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings and Revenue Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2021. Third-quarter 2021 net sales were $747.0 million, an increase of 15.4 percent compared to $647.3 million reported for the third quarter of 2020. On a currency-neutral basis, quarterly sales increased 13.8 percent compared to the same period in 2020. Third-qu

Bio-Rad Reports Third-Quarter 2021 Financial Results

Apple

GameStop

Genworth Financial

Helix Energy Solutions Group

Transocean

Tesla

Workhorse Group

Beating the market is hard, but it can be made easier by using the right set of tools. Here are the metrics to analyze penny stocks.

9 Moonshot Bets to Beat Hedge Funds at Their Own Game

Recovery in Clinical Diagnostics arm and strong growth in Droplet Digital PCR platform are expected to have contributed to Bio-Rad's (BIO) Q3 results.

Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

AGCO

DISH Network

Lennar

PerkinElmer

We believe that there are other stocks that are currently better valued than eBay's stock. EBAY's current price-to-operating income ratio (P/EBIT) of 16.7x is higher than levels of 13.3x for PerkinElmer, 10.7x for AGCO, 6.27x for Dish Network, 5.45x for Lennar and 5.45x for Bio-Rad Laboratories.

Which Stocks Are More Attractive Than eBay's Stock?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2021 on Thursday, October 28, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To listen, call 844-200-6205 within the U.S. or 929-526-1599 outside the U.S., access code: 535

Bio-Rad to Report Third-Quarter 2021 Financial Results, Thursday, October 28, 2021

Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.

Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise

Bio-Rad (BIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bio-Rad (BIO) Upgraded to Strong Buy: Here's Why

Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Bio-Rad Laboratories (BIO) Is Up 0.05% in One Week: What You Should Know

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now

Bio-Rad (BIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes Bio-Rad (BIO) a Good Fit for "Trend Investing"

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that management will participate in a Fireside Chat at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, at 11:40 AM (Pacific Time). A link to the live webcast of the presentation will be available in the “Conferences” area of Investor Relations on our website at bio-rad.com. About Bio-Rad Bio-Ra

Bio-Rad to Participate in the 2021 Virtual Wells Fargo Healthcare Conference

Arbor Realty Trust

Cathay General Bancorp

NBT Bancorp

RadNet

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like NBTB, BIO, RDNT, ABR and CATY.

New Analyst Coverage Puts Spotlight on These 5 Stocks

Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.

This Unknown Biotech Has a Secret Weapon for Outsized Returns

Costamare

Grindrod Shipping Holdings Ltd

Lifetime Brands

Veritiv

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength like VRTV, LCUT, GRIN, CMRE and BIO have a high chance of carrying the momentum forward.

5 Stocks With Recent Price Strength Amid Robust Reopening

Strong performance across the Life Science and Clinical Diagnostics businesses drove the top line for Bio-Rad (BIO).

Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?

Chemed

Materialise NV

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like CATY, BIO, CHE, MTLS and ABR.

5 Stocks to Buy as Analysts Initiate Coverage

Bio-Rad Laboratories, Inc. ( BIO , Financial) is maintaining the torrid rate of growth that has made it one of the most exceptional performers of the past half-decade. This year, the life science research and clinical diagnostics company has posted two more surging quarters that boosted its earnings per share significantly:

Bio-Rad Laboratories: Surging Growth Continues

Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Bio-Rad (BIO) Stock

Investors are optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies in the second quarter and raised 2021 guidance.

News for Bio-Rad Laboratories Stock (BIO)